You're using an outdated browser. To get the most out of this website, as well as many others, please consider upgrading to a modern browser, such as Google Chrome, Mozilla Firefox, or Microsoft Edge.

Open menu


Novartis and the NHS sign ‘landmark’ deal for cholesterol drug

A new agreement between Novartis and the NHS will enable “broad and rapid” access to cholesterol-lowering medicine Leqvio (inclisiran) for patients with long-term elevated LDL cholesterol (LDL-C), which is a known cause of atherosclerotic cardiovascular disease (ASCVD).